A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3353-3361

  Dunn, Sandra E ^a   Ehrlich, Michael ^a   Sharp, Nicholas J H ^c   Reiss, Kris ^b   Solomon, Gregory ^a   Hawkins, Rebecca ^a   Baserga, Renato ^b   Barrett, J Carl ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INVASION; CELL ADHESION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER; LUNG; LYMPH NODE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CODON; COLLAGEN; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LAMININ; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PACLITAXEL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRECIPITIN TESTS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0032146711     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Veronesi, U., Goldhirsch, A., and Yarnold, J. Breast cancer. In: M. Peckham, H. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, pp. 1243-1255. Oxford, United Kingdom: Oxford University Press, 1995.
2. Nemoto, T., Vana, J., Bedwani, R. N., Baker, H. W., McGregor, F. H., and Murphy, G. P. Management and survival of female breast cancer. Results of a national survey by the American College of Surgeons. Cancer (Phila.), 15: 2917-2924, 1980.
3. Fisher, B., and Slack, N., Number of lymph nodes examined and the prognosis of breast cancer. Surg. Gynecol. Obstet., 131: 79-83, 1970.
4. Peyrat, J. P., and Bonneterre, J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res. Treat., 22: 59-67, 1992.
5. Werner, H., Hernandex-Sanchez, C., Karneili, E., and LeRoith, D., The regulation of IGF-1 receptor gene expression. Int. J. Biochem. Cell Biol., 27: 987-994, 1995.
6. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., and Yamamoto, T., The product of the human c-erbB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science (Washington, DC), 232: 1644-1646, 1986.
7. Stewart, A. J., Johnson, M. D., May, F. E., and Westley, B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem., 265: 21172-21178, 1990.
8. Peyrat, J. P., Bonneterre, J., Hecquet, B., Vennin, P., Louchez, M. M., Fournier, C., Lefebvre, J., and Demaille, A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer, 29A: 492-497, 1993.
9. Giani, C., Cullen, K. J., Campani, K., and Rasmussen, A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ and immunohistochemistry study. Breast Cancer Res. Treat., 41: 43-50, 1996.
10. Bates, P., Fisher, R., Ward, A., Richardson, L., Hill, D. J., and Graham, C. F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer, 72: 1189-1193, 1995.
11. Osborne, C. K., Clemmons, D. R., and Arteaga, C. L. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem. Mol. Biol., 37: 805-809, 1990.
12. Dunn, S. E., Hardman, R., Kari, F. W., and Barrett, J. C., Insulin-like growth factor-I alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 6795-6797, 1997.
13. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J., Carter, D., Baserga, R., and Glazer, P. M., Insulin-like growth factor-1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.
14. Railo, M. J., Smitten, K. V., and Pekonen, F. The prognostic value of insulin-like growth factor-1 in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer, 30A: 307-311, 1994.
15. Leventhal, P. S., and Feldman, E. L. Insulin-like growth factors as regulators of cell motility: signaling mechanisms. Trends Endocrinol. Metab., 8: 1-6, 1997.
16. Doerr, M. E., and Jones, J. I. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor-1 stimulated chemotaxis of human breast cancer cells. J. Biol. Chem., 271: 2443-2447, 1996.
17. Scholar, E. M., and Toews, M. L. Inhibition of invasion of murine mammary carcinomas cells by the tyrosine kinase inhibitor genistein. Cancer Lett., 87: 159-162, 1994.
18. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res., 50: 717-721, 1990.
19. D'Ambrosio, C., Ferber, A., Resnicoff, M., and Baserga, R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56: 4013-4020, 1996.
20. Palmantier, R., Roberts, J. D., Glasgow, W. C., Eling, T. E., and Olden, K., Regulation of the adhesion of human breast carcinoma cell line to type IV collagen and vitronectin: role for lipoxygenase and protein kinase C. Cancer Res., 56: 2206-2212, 1996.
21. Annab, L. A., Dong, J. T., Futreal, P. A., Satoh, H., Oshimura, M., and Barrett, J. C. Growth and transformation suppressor genes for BHK Syrian hamster cells on human chromosomes 1 and 11. Mol. Carcinog, 6: 280-288, 1992.
22. Kenney, N. J., Smith, G. H., Rosenberg, K., Cutler, M. L., and Dickson, R. B., Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. Cell Growth Differ., 7: 1769-1781, 1996.
23. Dunn, S. E., and Cullen, J. M., Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs. Cancer Lett., 110: 177-180, 1996.
24. Richards, R. G., DiAugustine, R. P., Petrusz, P., Clark, G. C., and Sebastian, J., Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc. Natl. Acad. Sci. USA, 93: 12002-12007, 1996.
25. Goldstein, A. Biostatistics. An Introductory Text, 1-272. New York, NY: Macmillan Publishing Co., 1964.
26. Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B., The IGF-1 receptor in cell growth, transformation and apoptosis. Biochem. Biophys. Acta, 1332: F105-F126, 1997.
27. Resnicoff, M., Coppola, D., Sell, C., Rubin, R., Ferrone, S., and Baserga, R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54: 4848-4850, 1994.
28. Kurokawa, Y. Experiments on lymph node metastasis by intralymphatic inoculation of rat ascites tumor cells, with special reference to lodgement, passage and growth of tumor cells in lymph nodes. Gann, 61: 461-471, 1970.
29. Kumar, V., Cotran, R. S., and Robbins, S. L., Basic Pathology, Ed. 5, pp. 174-181. Philadelphia: W. B. Saunders Co., 1992.
30. Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y., Sakaue, H., Ando, A., Cavanieu, A., Calas, B., Grigorescu, F., Nishiyama, M., Waterfield, M. D., and Kasuga, M., Involvement of phosphotide 3-kinase in insulin-or IGF-1-induced membrane ruffling. EMBO J., 13: 2313-2321, 1994.
31. Miura, M., Li, S., and Baserga, R. Effect of mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res., 55: 663-667, 1995.
32. Prager, D., Li, H. L., Asa, S., and Melmed, S., Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I mutant. Proc. Natl. Acad. Sci. USA, 91: 2181-2185, 1994.
33. Burgaud, J. L., Resnicoff, M., and Baserga, R. Mutant IGF-1 receptors as dominant negatives for growth and transformation. Biochem. Biophys. Res. Commun., 214: 475-481, 1995.
34. Dunn, S. E., Kari, F. W., French, J., Leininger, J. R., Travlos, G., Wilson, R., and Barrett, J. C., Dietary restriction reduces insulin-like growth factor-1 levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res., 57: 4667-4672, 1997.
35. Kakizoe, T., Fair, W. R., Smith, P. H., Algaba, F., Ferrari, P., Grossman, H. B., Zirkali, Z., Tsukamoto, T., and Tachibana, M., What is the biology of invasion and metastasis of bladder cancer? Int. J. Urol., 2 (Suppl. 2): 58-63, 1995.
36. Pollak, M., Sem, A. W., Richard, M., Tetenes, E., and Bell, R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J. Natl. Cancer Inst. (Bethesda), 84: 966-971, 1992.
37. Burfeind, P., Chernicky, C. L., Rininsland, F., Ilan, J., and Ilan, J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA, 93: 7263-7268, 1996.
38. Long, L., Rubin, R., Baserga, R., and Brodt, P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 55: 1006-1009, 1995.
39. Pollak, M., Constantino, J., Polychronakos, C., Blauer, S., Guyda, H., Redmond, C., Fisher, B., and Margolese, R., Effect of tamoxifen on serum insulin like growth factor 1 levels in stage I breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 82: 1693-1697, 1990.
40. Colletti, R. B., Roberts, J. D., Devlin, J. T., and Copeland, K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res., 49: 1882-1884, 1989.
41. Huynh, H., and Pollak, M., Enhancement of tamoxifen-induced suppression of insulin-like growth factor 1 gene expression and serum level by a somatostatin analogue. Biochem. Biophys. Res. Commun., 203: 253-259, 1994.
42. Secreteriat, E. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339: 1-15, 71-85, 1992.